NeuroPathways Intervention for Brain Tumor Patients

Launched by MASSACHUSETTS GENERAL HOSPITAL · Jul 27, 2023

Keywords

ClinConnect Summary

The NeuroPathways Intervention for Brain Tumor Patients is a study designed to provide support and information to individuals diagnosed with high-grade brain tumors. The main goal of this trial is to see if a program that includes an information guide and personal coaching can help patients cope with their diagnosis. Researchers want to find out if patients find this program useful and if it's practical to implement. Participants will take part in coaching sessions, use the guide at their own pace, and fill out a few short surveys at different times during the study. Some may also be asked to share their thoughts in exit interviews.

To participate, individuals must be at least 18 years old, be a patient at the Massachusetts General Hospital Cancer Center, and have been diagnosed with a primary malignant brain tumor within the last six weeks. They should also be able to speak and read in English. However, those who have severe cognitive issues or whose doctors believe they shouldn't be approached for the study will not be eligible. This trial is currently recruiting participants, and it offers a chance for brain tumor patients to receive valuable support during a challenging time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18
• • Massachusetts General Hospital Cancer Center patient
• • Within 6 weeks of diagnosis with a primary malignant brain tumor
• • Able to speak and read in English
• Exclusion Criteria:
• • Inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia)
• • Deemed inappropriate to approach by patient's oncologist or study PI